Grey matter atrophy is associated with disability increase in natalizumab-treated patients

Ciampi, E; Pareto, D; Sastre-Garriga, J; Vidal-Jordana, A; Tur, C; Rio, J; Tintore, M; ... Montalban, X; + view all Ciampi, E; Pareto, D; Sastre-Garriga, J; Vidal-Jordana, A; Tur, C; Rio, J; Tintore, M; Auger, C; Rovira, A; Montalban, X; - view fewer (2017) Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Multiple Sclerosis Journal , 23 (4) pp. 556-566. 10.1177/1352458516656808 . Green open access

https://ift.tt/2CaOBYJ